EMA Authorised: Neupro (rotigotine) — UCB Pharma S.A.

View source ↗

Summary

The EMA has authorised Neupro (rotigotine) by UCB Pharma S.A. for Restless legs syndrome and Parkinson's disease.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease
• Restless Legs Syndrome

Drugs mentioned

• Neupro (rotigotine)

Snippet

Status: Authorised. Therapeutic area: Restless Legs Syndrome;Parkinson Disease. MAH: UCB Pharma S.A.. Decision date: 07/04/2026